# STRO catalysts: SUTRO BIOPHARMA, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/stro/catalysts

> SUTRO BIOPHARMA, INC. (STRO) has 1 upcoming catalyst. The next is the STRO-004 interim data readout, mid-2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, year only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for STRO?

SUTRO BIOPHARMA, INC. (STRO) has 1 upcoming catalyst. The next is the STRO-004 interim data readout, mid-2027. Press release filed with the SEC (EX-99): "Along with certain near-term milestone payments, the restructuring is expected to extend the Company's runway into at least mid-2027, following the planned release of initial clinical data from STRO-004, its next-generation Tissue Factor-targeting exatecan ADC, and initiation of clinical studies for at least one other ADC program." [Calendar and source filings](https://sec-api.dev/companies/stro/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-25-269833, https://www.sec.gov/Archives/edgar/data/1382101/000119312525269833/stro-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2025-11-06. Cite: https://sec-api.dev/companies/stro/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | SUTRO BIOPHARMA, INC. |
| Ticker | STRO (Nasdaq) |
| SEC CIK | 1382101 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/stro |

## Cash runway

Cash $142.2M as of 2026-09-30; quarterly burn $22.5M; about 19.0 months of runway at that rate (XBRL company facts, accession 0001193125-26-458680).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2023 | [Luvelta trial start](https://sec-api.dev/pdufa/luvelta) | STRO | platinum-resistant ovarian cancer in June 2023 | completed | "Following the studies discussed above, we initiated a Phase 2/3 study, the REFRαME-O1 study, of luvelta for the treatment of platinum-resistant ovarian cancer in June 2023." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1382101/000095017024126407/stro-20240930.htm)) |
| Aug 2024 | [Luvelta trial start](https://sec-api.dev/pdufa/luvelta) | STRO | FRα-expressing non-small cell lung cancer, or NSCLC, with luvelta | completed | "Our IND for the treatment of FRα-expressing non-small cell lung cancer, or NSCLC, with luvelta was cleared by the FDA in the first half of 2024 and we initiated the Phase 2 study in August 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1382101/000095017024126407/stro-20240930.htm)) |
| November 13, 2024 | [SUTRO BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/stro/catalysts) | STRO |  | completed | "Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000095017024126382/stro-ex99_1.htm)) |
| 2025 | [Luvelta interim data readout](https://sec-api.dev/pdufa/luvelta) | STRO |  | scheduled | "A Phase 2 trial for the treatment of NSCLC is underway, with initial data expected in 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000095017024126382/stro-ex99_1.htm)) |
| 1H 2025 | [MVASI® (bevacizumab) interim data readout](https://sec-api.dev/pdufa/bevacizumab) | STRO |  | scheduled | "In addition, we are enrolling patients in the expansion phase of the bevacizumab combination Phase 1b study and expect to present initial data from this trial in in the first half of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1382101/000095017024126407/stro-20240930.htm)) |
| March 13, 2025 | [SUTRO BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/stro/catalysts) | STRO |  | completed | "Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000095017025038879/stro-ex99_1.htm)) |
| May 8, 2025 | [SUTRO BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/stro/catalysts) | STRO |  | completed | "Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000095017025067061/stro-ex99_1.htm)) |
| August 7, 2025 | [SUTRO BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/stro/catalysts) | STRO |  | completed | "Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000095017025105159/stro-ex99_1.htm)) |
| August 26, 2025 | [Luveltamab tazevibulin primary completion](https://sec-api.dev/pdufa/luveltamab-tazevibulin) | STRO | Ovarian Cancer; Epithelial Ovarian Cancer; Fallopian Tube Cancer | withdrawn | "NCT05870748 (REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1): Overall Status TERMINATED; Phase PHASE2, PHASE3; Primary Completion 2025-08-26 (ACTUAL); Lead Sponsor Sutro Biopharma, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05870748)) |
| November 6, 2025 | [SUTRO BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/stro/catalysts) | STRO |  | completed | "Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000119312525269833/stro-ex99_1.htm)) |
| March 23, 2026 | [SUTRO BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/stro/catalysts) | STRO |  | completed | "Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000119312526119844/stro-ex99_1.htm)) |
| mid-2026 | [STRO-004 interim data readout](https://sec-api.dev/pdufa/stro-004) | STRO |  | scheduled | "The Company expects to report initial clinical data in mid-2026, including safety and tolerability, pharmacokinetic exposure, and early activity data." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000119312526224065/stro-ex99_1.htm)) |
| May 14, 2026 | [SUTRO BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/stro/catalysts) | STRO |  | completed | "Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000119312526224065/stro-ex99_1.htm)) |
| Q3 2026 | [STRO-006 trial start](https://sec-api.dev/pdufa/stro-006) | STRO |  | scheduled | "We expect to initiate a Phase 1 clinical trial in connection with STRO-006 in the third quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1382101/000119312526345748/stro-20260630.htm)) |
| August 12, 2026 | [STRO-004 earnings report](https://sec-api.dev/pdufa/stro-004) | STRO |  | completed | "Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000119312526345733/stro-ex99_1.htm)) |
| Oct 2026 | [STRO-006 trial start](https://sec-api.dev/pdufa/stro-006) | STRO | advanced or metastatic solid tumors | completed | "In October 2026, the Company announced the first patient dosed in a Phase 1, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics and preliminary antitumor activity of STRO-006 as a monotherapy in adults with advanced or metastatic solid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000119312526458641/stro-ex99_1.htm)) |
| November 12, 2026 | [SUTRO BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/stro/catalysts) | STRO |  | completed | "Sutro Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000119312526458641/stro-ex99_1.htm)) |
| mid-2027 | [STRO-004 interim data readout](https://sec-api.dev/pdufa/stro-004) | STRO |  | scheduled | "Along with certain near-term milestone payments, the restructuring is expected to extend the Company's runway into at least mid-2027, following the planned release of initial clinical data from STRO-004, its next-generation Tissue Factor-targeting exatecan ADC, and initiation of clinical studies for at least one other ADC program." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000119312525269833/stro-ex99_1.htm)) |

## Drugs

- [Luvelta](https://sec-api.dev/pdufa/luvelta): platinum-resistant ovarian cancer in june 2023, frα-expressing non-small cell lung cancer, or nsclc, with luvelta
- [Luveltamab tazevibulin](https://sec-api.dev/pdufa/luveltamab-tazevibulin): Ovarian Cancer
- [STRO-004](https://sec-api.dev/pdufa/stro-004): 
- [STRO-006](https://sec-api.dev/pdufa/stro-006): advanced or metastatic solid tumors

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/stro/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "STRO catalysts: SUTRO BIOPHARMA, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/stro/catalysts

```bibtex
@misc{secapidev_companies_stro_catalysts_20261116,
  title        = {STRO catalysts: SUTRO BIOPHARMA, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/stro/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_stro_catalysts_20261116","title":"STRO catalysts: SUTRO BIOPHARMA, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/stro/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
